Adjuvant treatment of resected lung cancer

Proceedings of the American Thoracic Society

Volumn 6, Issue 2, 2009, Pages 194-200

  Chhatwani, Laveena ^a   Cabebe, Elwyn ^b   Wakelee, Heather A ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Lung cancer; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; UFT; VASCULOTROPIN; VINBLASTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; DISEASE MARKER; DRUG TARGETING; EARLY CANCER; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 65349189881     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200807-068LC     Document Type: Conference Paper

References (46)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
3. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage Ib-IIIa non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
4. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al. Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
5. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
6. Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev 2007;3:CD006157.
7. Burdett S, Stewart LA, Rydzewska L. A systematic review and metaanalysis of the literature: Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611-621.
8. Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski T, Maiorino A, Hetzel M, Visseren-Grul C, Torri V. A phase III randomized study of surgery alone or surgery plus pre- operative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): follow-up data of Ch.E.S.T. [abstract]. J Clin Oncol 2008;26(Suppl):399s.
9. The lung cancer study group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986;315:1377-1381.
10. Holmes EC, Bleehen NM, Le Chevalier T, Ettinger D, Jett JR, Johnson D, Komaki R, Saijo N, Sause W, Trovo M, Van Houtte P, Wulfrank D. Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report. Lung Cancer 1991;7:11-13.
11. Non-small cell lung cancer collaborative group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
12. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer: Eastern cooperative oncology group. N Engl J Med 2000;343:1217-1222.
13. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the big lung trial. Eur J Cardiothorac Surg 2004;26:173-182.
14. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIa non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
15. Le Chevalier T, Dunant A, Arriagada R, Bergman B, Chabowski M, LePechoux C, Kozlowski M, Tarayre M, Pignon JP; IALT Collaborative Group. Long-term results of the international adjuvant lung cancer trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008;26(Suppl):399s.
16. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA. Adjuvant vinorelbine and cisplatin in elderly patients: national cancer institute of Canada and intergroup study JBR.10. J Clin Oncol 2007;25:1553-1561.
17. Strauss GMHJ, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schilsky RL, Green MR. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib non-small cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633; abstr 7019. J Clin Oncol 2004;22.
18. Strauss GMHJ, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schilsky RA, Vokes EE, Green MR. Adjuvant chemotherapy in stage Ib non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633; abstr 7007. J Clin Oncol 2006;24.
19. Stewart LA, Burdett S, Tierney JF, Pignon J; NSCLC Collaborative Group. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT); abstr 7552. J Clin Oncol 2007;25.
20. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta- analysis of randomized clinical trials. Lung Cancer 2008;63:50-57.
21. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
22. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Metaanalysis of randomized clinical trials comparing cisplatin to carbopla- tin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
23. Sedrakyan A, Van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414-419.
24. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23: 4999-5006.
25. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
26. PORT meta-analysis trialists group. Postoperative radiotherapy in nonsmall-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-263.
27. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small- cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006.
28. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, Pairolero PC, Allen MS, Shaw EG, Marks RS, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 1997;80:1399-1408.
29. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern cooperative oncology group (ECOG) trial e3590. Lung Cancer 2005;48:389-397.
30. Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001;19:3912-3917.
31. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
32. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G. Rrm1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24: 4731-4737.
33. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-719.
34. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-5247.
35. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983.
36. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808.
37. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
38. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (IRESSA survival evaluation in lung cancer). Lancet 2005;366:1527-1537.
39. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG s0023. J Clin Oncol 2008;26:2450-2456.
40. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
41. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, Leighl N, Mezger J, Archer V, Reck M. Randomised, double-blind multicentre phase iii study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (nsclc): B017704; abstr lba7514. J Clin Oncol 2007;25.
42. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, RamiPorta R, Postmus PE, Rusch V, Sobin L. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
43. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, et al. Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIa re- sectable non small-cell lung cancer guideline. J Clin Oncol 2007;25: 5506-5518.
44. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S-242S.
45. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer-stage IIIa: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:243S-265S.
46. Strauss GM, Herndon JE, 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage Ib non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group b, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol 2008;26:5043-5051.